Tim Brunson DCH

Welcome to The International Hypnosis Research Institute Web site. Our intention is to support and promote the further worldwide integration of comprehensive evidence-based research and clinical hypnotherapy with mainstream mental health, medicine, and coaching. We do so by disseminating, supporting, and conducting research, providing professional level education, advocating increased level of practitioner competency, and supporting the viability and success of clinical practitioners. Although currently over 80% of our membership is comprised of mental health practitioners, we fully recognize the role, support, involvement, and needs of those in the medical and coaching fields. This site is not intended as a source of medical or psychological advice. Tim Brunson, PhD

Inventing stories: forcing witnesses to fabricate entire fictitious events.



Studies of the forced fabrication effect have shown that participant witnesses are prone to developing false memories for specific items or details that they have been forced to fabricate earlier (e.g., what type of hat someone wore). Building on these earlier findings, the present study assessed whether participants would develop false memories if forced to fabricate entire fictitious events that were more complex and extended in time and involved people, locations, and actions that they had never seen. Participants vehemently resisted fabricating these events, and false memory development over the short term (1-week recognition test) was limited. However, after 8 weeks, participants freely reported their forced fabrications nearly 50% of the time and did so even when they had correctly and publicly rejected them earlier on the 1-week recognition test. This is the first evidence that participant witnesses will freely incorporate into their eyewitness accounts entire fictitious events that they have earlier been forced to fabricate.

Psychon Bull Rev. 2008 Dec;15(6):1190-5. Chrobak QM, Zaragoza MS. Department of Psychology, Kent State University, Kent, OH 44242, USA. qchrobak@kent.edu

Smoking cessation with varenicline: a suicidal fatality.



The most effective smoking cessation programs involve a combination of pharmacotherapy and behavioral and/or cognitive counseling to improve abstinence rates. Varenicline (Champix in France and the U.K.), the most recently approved agent for tobacco cessation, is the first drug in a new class (alpha4beta2 partial agonist) that binds to the nicotinic receptors to release dopamine and alleviate withdrawal symptoms. As the literature reports psychiatric disorders being linked to varenicline as an issue, we describe the case of a man who committed suicide while receiving therapy with this drug. The deceased (a 39-year-old man) was found dead at his home address with slash wounds to his wrist. The deceased had been prescribed varenicline for several months at a dose of 1 tablet (1 mg) twice daily. The lab received a blood specimen to perform a screening for unknown drugs, including varenicline. Because of its selectivity and sensitivity, liquid chromatography coupled to tandem mass spectrometry was chosen as the best approach to develop a procedure for varenicline. One milliliter of blood was extracted with 5 mL of a mixture of dichloromethane/isopropanol/n-heptane (25:10:65) at pH 9.5 (phosphate buffer) in the presence of diazepam-d(5), which was used as an internal standard (IS). The resultant blood extract was separated on an XTerra MS C18 column using a gradient of acetonitrile and formic acid in water. Drugs were identified by three or two transitions (m/z 212 > 169, 212 > 183, and 212 > 195 and 290 > 154 and 290 > 198 for varenicline and IS, respectively). The limit of quantitation of varenicline was 1 ng/mL. The concentration of varenicline in the blood was determined to be 10 ng/mL. This concentration could not be compared with therapeutic levels, as there are no therapeutic concentrations reported in the literature. Because of its potential effects on behavior, the influence of the drug on the mental functioning of the user should be considered in cases of suicide.

J Anal Toxicol. 2009 Mar;33(2):118-20. Kintz P, Evans J, Villain M, Cirimele V. Laboratoire ChemTox, 3 rue Gruninger, 67400 Illkirch, France. pascal.kintz@wanadoo.fr

© 2000 - 2025The International Hypnosis Research Institute, All Rights Reserved.

Contact